Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about MERCK AND COMPANY
12:56p MERCK AND : U.S. FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in M..
12:46p MERCK AND : KEYTRUDA® (pembrolizumab) More Than Doubled Median Overall Survival ..
10/16 ASTRAZENECA : Pharma and medtech industries prepare for hard Brexit
10/16 MERCK AND : Makes $3 Million Charitable Donation to Support Swim Across America
10/16 MERCK AND : Joins with the American Liver Foundation to Educate U.S. Veterans on..
10/16 BERGENBIO : BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured..
10/16 BERGENBIO : BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured..
10/13 MERCK AND : Provides Update on Anacetrapib Development Program
10/12 MERCK : Makes $3 Million Charitable Donation to Support Swim Across America
10/12 MERCK : Joins with the American Liver Foundation to Educate U.S. Veterans on Chr..
10/12 MERCK AND : - Six year Efficacy Data for GARDASIL 9 Presented at EUROGIN 2017 Co..
10/11DJMERCK AND : Ebola Vaccines Show Promise in New Study
10/11 MERCK : Provides Update on Anacetrapib Development Program
10/10 MERCK AND : Six-year Efficacy Data for GARDASIL® 9 Presented at EUROGIN 2017 Con..
10/06 MERCK AND : Highlights Ongoing Commitment to Fighting Infectious Diseases with 4..
More most relevant news
All news about MERCK AND COMPANY
12:56p MERCK AND : U.S. FDA Accepts Regulatory Submission for LYNPARZA® (olaparib) in M..
12:46p MERCK AND : KEYTRUDA® (pembrolizumab) More Than Doubled Median Overall Survival ..
10/16 ASTRAZENECA : Pharma and medtech industries prepare for hard Brexit
10/16 MERCK AND : Makes $3 Million Charitable Donation to Support Swim Across America
10/16 MERCK AND : Joins with the American Liver Foundation to Educate U.S. Veterans on..
10/16 BERGENBIO : BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured..
10/16 BERGENBIO : BGB324, BerGenBio's Selective First-in-Class AXL Inhibitor, Featured..
10/13 MERCK AND : Salk Researchers Awarded $2.5 Million for Innovative Pancreatic Canc..
10/13 MERCK AND : Provides Update on Anacetrapib Development Program
10/12 MERCK : Makes $3 Million Charitable Donation to Support Swim Across America
More news
Sector news : Pharmaceuticals - NEC
06:43p FTSE rises to record close, blue-chips shrug off Reckitt blip
04:43p ALLERGAN : ruling casts doubt on tribal patent strategy
03:09pDJELI LILLY AND : Lilly To Develop Cancer Vaccine Products with CureVac -- Market ..
08:52aDJASTRAZENECA : Breast-Cancer Drug Gets Priority Review From FDA
08:48aDJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
08:24a RECKITT BENCKISER : to form two business units for better focus
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03:32p A Bit About Biopharma Investing
01:35p THE VISION IS CLEAR : Listen To Merck And Invest In Microcap KalVista Pharmaceut..
11:23a Only 16 Of 61 Are 'Safer' Dividend Healthcare Dogs For October
09:36a HEALTHCARE DOGFIGHT : Owens & Minor Edges GlaxoSmithKline As Top Broker Pick For..
08:58a Exploring AstraZeneca's Two-Prong Assault On Lung Cancer
07:03a Merck's Keytruda doubles survival over chemo in lung cancer study
Latest Tweets
07:21pWeekly Analysts’ Ratings Updates for Merck & $MRK  
07:11pMerck & Company given $70.00 PT by BMO Capital Markets. buy rating.  
06:38pBecause apparently the individual materials that form the composite aren’t re..
3
05:03pOn The Fly: Top five analyst upgrades $MRK $GPRO $OMC $MGA $GWW  
04:51pPadding its lung cancer lead, Merck's Keytruda helped PD-L1 patients live 30 .. 
More tweets
Qtime:297
Financials ($)
Sales 2017 40 272 M
EBIT 2017 13 680 M
Net income 2017 5 795 M
Debt 2017 8 102 M
Yield 2017 2,98%
P/E ratio 2017 31,54
P/E ratio 2018 18,81
EV / Sales 2017 4,48x
EV / Sales 2018 4,41x
Capitalization 172 B
Chart MERCK AND COMPANY
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 69,6 $
Spread / Average Target 10%
EPS Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY7.68%172 423
JOHNSON & JOHNSON18.42%377 880
NOVARTIS13.23%225 650
ROCHE HOLDING LTD.5.20%217 022
PFIZER11.88%215 576
AMGEN25.17%135 858